Andrea Ciarmiello

List of Publications by Year
in descending order

93	2,509	270111	232693
papers	citations	25 h-index	48 g-index

98	98	98	3748
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact of Tracer Retention Levels on Visual Analysis of Cerebral [18F]- Florbetaben Pet Images. Current Radiopharmaceuticals, 2021, 14, 70-77.	0.3	1
2	Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. Current Radiopharmaceuticals, 2020, 13, 63-79.	0.3	40
3	Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-Î² neocortical deposition. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2090-2098.	3.3	11
4	The brain cognitive reserve hypothesis: A review with emphasis on the contribution of nuclear medicine neuroimaging techniques. Journal of Cellular Physiology, 2019, 234, 14865-14872.	2.0	15
5	Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels. Nuclear Medicine Communications, 2019, 40, 258-263.	0.5	3
6	11C-choline PET/CT predicts survival in prostate cancer patients with PSAâ€‰<â€‰1 NG/ml. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 921-929.	3.3	14
7	Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimerâ€™s disease in mild cognitive impairment patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 288-296.	3.3	21
8	[68Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications. Current Radiopharmaceuticals, 2019, 12, 11-22.	0.3	6
9	The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 962-969.	3.3	1
10	Stroke chameleon (cortical hand syndrome) in a patient with moderate carotid stenosis: a neurological double-trouble. Neurological Sciences, 2018, 39, 1125-1127.	0.9	1
11	Will 68 Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.1	0
12	Â¿ConstituirÃ¡n en el futuro los radioligandos de 68 Ga-PSMA la Ãºnica elecciÃ³n de la Medicina Nuclear para el cÃ¡ncer de prÃ³stata? ActualizaciÃ³n clÃ¡nica. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.0	3
13	Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives. Clinical and Translational Imaging, 2018, 6, 483-485.	1.1	8
14	PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. Current Radiopharmaceuticals, 2018, 11, 4-13.	0.3	28
15	PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1751-1776.	3.3	45
16	Molecular Imaging of Huntington's Disease. Journal of Cellular Physiology, 2017, 232, 1988-1993.	2.0	6
17	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation, 2017, 40, 1265-1269.	1.8	4
18	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2017, , 467-505.		1

#	Article	IF	Citations
19	Targeted Therapy Towards Cancer-A Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 311-317.	0.9	13
20	Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Current Radiopharmaceuticals, 2017, 10, 6-15.	0.3	8
21	PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives. Current Radiopharmaceuticals, 2017, 10, 184-194.	0.3	6
22	11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients. Current Radiopharmaceuticals, 2017, 10, 195-202.	0.3	5
23	Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. , 2017, , 1103-1137.		0
24	Hybrid Imaging in Pediatric Central Nervous System Disorders. , 2016, , 195-217.		0
25	PET/CT Versus PET/MRI. , 2016, , 297-310.		1
26	How reliable is 18FDG PET for predicting the onset of Huntingtonâ€™s disease?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2180-2182.	3.3	2
27	Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Annals of Nuclear Medicine, 2016, 30, 234-241.	1.2	11
28	Hybrid Imaging in Cerebrovascular Disease: Ischemic Stroke. , 2016, , 251-262.		0
29	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2016, , 1-40.		0
30	Multimodality Imaging of Huntingtonâ€™s Disease. , 2016, , 221-230.		0
31	FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects. Current Radiopharmaceuticals, 2015, 8, 69-75.	0.3	16
32	Early detection of encephalitis with 18F-FDG PET/CT. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 188-190.	0.0	1
33	Performance comparison of two resolution modeling PET reconstruction algorithms in terms of physical figures of merit used inÂquantitative imaging. Physica Medica, 2015, 31, 468-475.	0.4	19
34	Post-therapy normalization of brain FDG-PET in Morvan's syndrome. Journal of the Neurological Sciences, 2015, 353, 175-176.	0.3	4
35	Nuclear medicine training and practice in Italy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1945-1947.	3.3	1
36	Clinical Applications of Choline PET/CT in Brain Tumors. Current Pharmaceutical Design, 2014, 21, 121-127.	0.9	40

#	Article	IF	Citations
37	Hybrid SPECT/CT Imaging in Neurology. Current Radiopharmaceuticals, 2014, 7, 5-11.	0.3	12
38	Perspectives on PET/MR Imaging: Are We Ready for Clinical Use?. Journal of Nuclear Medicine, 2014, 55, 529-530.	2.8	10
39	From Homo sapiens to Homo in nexu (connected man): could functional imaging redefine the brain of a â€œnew human speciesâ€?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1385-1387.	3.3	6
40	SPECT Radiopharmaceuticals for Dementia. Current Radiopharmaceuticals, 2014, 6, 192-207.	0.3	3
41	Parametric MR Dynamic Imaging for Breast Lesions Characterization and Prediction of Lymph Nodes Involvement. Current Radiopharmaceuticals, 2014, 7, 91-99.	0.3	1
42	Microalbuminuria predicts silent myocardial ischaemia in type 2 diabetes patients. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 548-557.	3.3	13
43	Multiagent imaging of the brain. Clinical and Translational Imaging, 2013, 1, 365-376.	1.1	2
44	Pediatric Cancers. , 2013, , 663-687.		0
45	Weighted registration of ¹²³<scp>I</scp>â€<scp>FP</scp>â€CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake. Journal of Cellular Physiology, 2013, 228, 2086-2094.	2.0	7
46	18F-fluorodeoxyglucose-PET as a biomarker in Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 489-491.	1.2	0
47	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. PLoS ONE, 2013, 8, e74548.	1.1	76
48	Auditory Hallucinations as the Only Presenting Symptom of Right-Parietal Spontaneous Hemorrhage: FDG-PET Evidence of Corpus Callosum Hyperactivity. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E28-E29.	0.9	3
49	PET/MRI and the revolution of the third eye. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1519-1524.	3.3	35
50	18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1030-1036.	3.3	60
51	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	1.6	64
52	Seeking Brain Biomarkers for Preventive Therapy in Huntington Disease. CNS Neuroscience and Therapeutics, 2011, 17, 368-386.	1.9	21
53	Imaging of neuroinflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2198-2201.	3.3	11
54	Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG₃₃ repeat length in the Huntington's disease gene. Movement Disorders, 2011, 26, 925-927.	2.2	24

#	Article	IF	Citations
55	PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. Journal of Cellular Physiology, 2011, 226, 948-961.	2.0	16
56	Targeted â€“ Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?. Reviews on Recent Clinical Trials, 2011, 6, 259-265.	0.4	18
57	Key role of nuclear medicine in seeking biomarkers of Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1124-1127.	3.3	13
58	Cerebral Blood Flow in Depressed Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1844-1851.	1.0	20
59	Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1113-1120.	3.3	52
60	Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease. CNS Neuroscience and Therapeutics, 2009, 15, 1-11.	1.9	69
61	Unexpected Detection of Melanoma Brain Metastasis by PET With Iodine-124 Î²CIT. Clinical Nuclear Medicine, 2009, 34, 698-699.	0.7	13
62	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. BMJ Case Reports, 2009, 2009, bcr0820080711-bcr0820080711.	0.2	2
63	Neuroprotective effects of riluzole in Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 221-222.	3.3	9
64	SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. Clinical Cancer Research, 2007, 13, 2738-2744.	3.2	39
65	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1411-1413.	0.9	8
66	The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction. European Journal of Neurology, 2006, 13, 408-415.	1.7	15
67	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell, 2006, 9, 459-471.	7.7	226
68	Juvenile Huntington's disease: Does a dosage-effect pathogenic mechanism differ from the classical adult disease?. Mechanisms of Ageing and Development, 2006, 127, 208-212.	2.2	62
69	Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. Journal of Nuclear Medicine, 2006, 47, 215-22.	2.8	201
70	Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene, 2005, 24, 3427-3435.	2.6	137
71	Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 879-887.	3.3	30
72	Italian Huntington disease patients-data and tissue bank. Neurological Sciences, 2003, 24, 215-216.	0.9	5

#	Article	IF	Citations
73	Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. NeuroImage, 2003, 18, 360-366.	2.1	82
74	Stereotaxy-Based Regional Brain Volumetry Applied to Segmented MRI: Validation and Results in Deficit and Nondeficit Schizophrenia. NeuroImage, 2002, 17, 373-384.	2.1	49
75	Similar TIAs and corresponding alterations in regional cerebral perfusion in Caucasian monozygotic twins with moyamoya disease. Clinical Imaging, 2002, 26, 378-381.	0.8	4
76	Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 809-814.	3.3	16
77	Assessment of scanner performance and normalization of estimated relaxation rate values. Magnetic Resonance Imaging, 2001, 19, 123-128.	1.0	1
78	Measurement of global brain atrophy in alzheimer's disease with unsupervised segmentation of spin-echo MRI studies. Journal of Magnetic Resonance Imaging, 2000, 11, 260-266.	1.9	27
79	Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis. Journal of Magnetic Resonance Imaging, 2000, 12, 799-807.	1.9	91
80	Scintigraphic Detection of Multidrug Resistance in Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 327-337.	0.7	31
81	Moyamoya disease in Italian monozygotic twins. Neurology, 1999, 53, 1332-1332.	1.5	23
82	Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.. Journal of Clinical Oncology, 1998, 16, 1677-1683.	0.8	146
83	In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 150-159.	2.2	150
84	Neurologic complications of Hodgkin's disease: A case history. Annals of Oncology, 1997, 8, 593-600.	0.6	5
85	White matter lesion detection in multiple sclerosis: improved interobserver concordance with multispectral MRI display. Journal of Neurology, 1997, 244, 586-590.	1.8	9
86	Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach. Magnetic Resonance in Medicine, 1997, 37, 84-93.	1.9	89
87	Multiparametric display of spin-echo data from MR studies of brain. Journal of Magnetic Resonance Imaging, 1995, 5, 217-225.	1.9	27
88	Assessment of left ventricular regional function by radionuclide angiography: Effects of number of sectors on repeatability. Nuclear Medicine and Biology, 1994, 21, 883-887.	0.3	2
89	Effects of induced asynchrony on left ventricular diastolic function in patients with coronary artery disease. Journal of the American College of Cardiology, 1993, 21, 1124-1131.	1.2	73
90	Simultaneous Display of Multiple MR Parameters with â€œQuantitative Magnetic Color Imagingâ€• Journal of Computer Assisted Tomography, 1992, 16, 634-640.	0.5	23

#	Article	IF	Citations
91	Left ventricular diastolic function in systemic sclerosis: assessment by radionuclide angiography. Journal of Nuclear Medicine, 1992, 33, 68-72.	2.8	9
92	Assessment of left ventricular diastolic function: comparison of contrast ventriculography and equilibrium radionuclide angiography. Journal of Nuclear Medicine, 1991, 32, 1849-53.	2.8	8
93	Effects of intravenous verapamil on left ventricular relaxation and filling in stable angina pectoris. American Journal of Cardiology, 1990, 66, 818-825.	0.7	17